Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

25.45
+0.70002.83%
Post-market: 25.450.00000.00%16:59 EDT
Volume:296.73K
Turnover:7.49M
Market Cap:699.90M
PE:-9.47
High:25.77
Open:25.17
Low:24.78
Close:24.75
Loading ...

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

StockStory
·
11 Mar

Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm NDA Submission and Strong Financial Position

TIPRANKS
·
11 Mar

Prelude Therapeutics Reports 2024 Financial Results

TIPRANKS
·
11 Mar

Aligos Therapeutics Advances Pipeline Amid Financial Challenges

TIPRANKS
·
11 Mar

Lineage Cell Therapeutics: 2024 Financial Results and Strategic Progress

TIPRANKS
·
11 Mar

Cathie Wood’s ARK Investment buys 485K shares of Beam Therapeutics today

TIPRANKS
·
11 Mar

Prescient Therapeutics Appoints Chair; Shares Fall 7%

MT Newswires Live
·
11 Mar

OnKure Therapeutics price target lowered to $30 from $35 at Oppenheimer

TIPRANKS
·
11 Mar

OnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c)

TIPRANKS
·
11 Mar

Prescient Therapeutics Announces New Board Chair Amidst Growth Phase

TIPRANKS
·
11 Mar

Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges

TIPRANKS
·
11 Mar

Promising Clinical Developments and Strategic Advancements Support Buy Rating for Tenaya Therapeutics

TIPRANKS
·
11 Mar

Mineralys Therapeutics Launches $250 Million Public Offering of Shares

MT Newswires Live
·
11 Mar

Tenaya Therapeutics reports Q4 EPS (28c), consensus (31c)

TIPRANKS
·
11 Mar

Press Release: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Dow Jones
·
11 Mar

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Business Wire
·
11 Mar